[1] Xiao AY, Tan ML, Wu LM, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol, 2016, 1(1):45-55.
[2] Lotte B, Rogier PV, Stefan AB, et al. Acute Pancreatitis. Lancet, 2020, 396(10252):726-734.
[3] Eslam M, Sanyal AJ, George J, et al. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology, 2020, 158(7):1999-2014.
[4] 夏明锋,卞华,高鑫. 从非酒精性脂肪肝到代谢相关性脂肪肝命名变化的思考. 中华糖尿病杂志, 2020, 12(7): 445-450.
[5] Mitra S, De A, Chowdhury A. Epidemiology of non-alcoholic and alcoholic fatty liver diseases. Transl Gastroenterol Hepatol, 2020, 5:16.
[6] Wong SW, Chan WK. Epidemiology of non-alcoholic fatty liver disease in Asia. Indian J Gastroenterol, 2020, 39(1):1-8.
[7] Hou S, Tang X, Cui H, et al. Fatty liver disease is associated with the severity of acute pancreatitis:A systematic review and meta-analysis. Int J Surg, 2019, 65:147-153.
[8] Mikolasevic I, Orlic L, Poropat G, et al. Nonalcoholic fatty liver and the severity of acute pancreatitis. Eur J Intern Med, 2017, 38:73-78.
[9] Wu D, Zhang M, Xu S, et al. Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. Biomed Res Int, 2019, 2019:9583790.
[10] Yoon SB, Lee IS, Choi MH, et al. Impact of Fatty Liver on Acute Pancreatitis Severity. Gastroenterol Res Pract, 2017, 2017:4532320.
[11] Mikolasevic I, Milic S, Orlic L, et al. Metabolic syndrome and acute pancreatitis. Eur J Intern Med, 2016, 32:79-83.
[12] Okamura T, Hashimoto Y, Hamaguchi M, et al. Clinical characteristics and longitudinal changes of patients with non-alcoholic fatty liver disease in 2 decades: the NAGALA study. BMC Gastroenterol, 2021, 21(1):223.
[13] Szentesi A, Párniczky A, Vincze ?, et al. Multiple Hits in Acute Pancreatitis: Components of Metabolic Syndrome Synergize Each Other′s Deteriorating Effects. Front Physiol, 2019, 10:1202.
[14] Bonfrate L, Wang DQ, Garruti G, et al. Obesity and the risk and prognosis of gallstone disease and pancreatitis. Best Pract Res Clin Gastroenterol, 2014, 28(4):623-635.
[15] Lee YH, Pratley RE. The evolving role of inflammation in obesity and the metabolic syndrome. Curr Diab Rep, 2005, 5(1):70-75.
[16] Frossard JL, Lescuyer P, Pastor CM. Experimental evidence of obesity as a risk factor for severe acute pancreatitis. World J Gastroenterol, 2009, 15(42):5260-5265.
[17] Kiss L, F?r G, Mátrai P, et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis. Sci Rep, 2018, 8(1):14096.
[18] Li HB, Jin C, Chen Y, et al. Inflammasome activation and metabolic disease progression. Cytokine Growth Factor Rev, 2014, 25(6):699-706.
[19] Wang Q, Yan H, Wang G, et al. RNA sequence analysis of rat acute experimental pancreatitis with and without fatty liver: a gene expression profiling comparative study. Sci Rep, 2017, 7(1):734.
[20] Shen Z, Wang X, Zhen Z, et al. Metabolic syndrome components and acute pancreatitis: a case-control study in China. BMC Gastroenterol, 2021, 21(1):17.
[21] 王彩平,段顺元,刘玮. 2型糖尿病合并急性胰腺炎发病机制的研究进展. 当代医药论丛, 2017, 15(22): 38-40.
[22] 任士萌,梅璐,黄煌,等. 非酒精性脂肪性肝病患者肠道菌群及生物化学指标相关性分. 中华肝脏病杂志, 2019, 27(5): 369-375.
[23] 黄莹,彭剑桥,王宇鹏,等. 肠道菌群失衡与急性胰腺炎易位感染的关系. 中国微生态学杂志, 2019, 31(1): 17-20, 24.
[24] 郭易楠,刘瑞霞,阴赪宏. 肠道菌群在急性胰腺炎发生发展中的作用. 中国医刊, 2019, 54(6): 592-594.
[25] 张荣芳,吴敏娜,张静,等. 2型糖尿病合并急性胰腺炎大鼠肠道菌群变化及其与胰腺炎病情进展的关系. 山东医药, 2019, 59(3): 30-34.
[26] 黄瑞贤,汪保灿,范建高. 非酒精性脂肪性肝病与胆道疾病关系的研究进展. 中华肝脏病杂志, 2017, 25(8): 633-636.
[27] Bai Y, Liu Y, Jia L, et al. Severe acute pancreatitis in China: etiology and mortality in 1976 patients. Pancreas, 2007, 35(3):232-237.
[28] 李辉,贾文秀,李风华,等. 急性胰腺炎发病机制研究. 胃肠病学和肝病学杂志, 2020, 29(4): 379-383.
[29] 冯磊,张轶,徐德全,等. 急性胆源性胰腺炎诊治进展. 中国普外基础与临床杂志, 2019, 26(4): 508-512. |
